Bionano Genomics, Inc. (BNGO) Bundle
An Overview of Bionano Genomics, Inc. (BNGO)
General Summary of Bionano Genomics, Inc. (BNGO)
Bionano Genomics, Inc. is a genomic technology company headquartered in San Diego, California. The company specializes in optical genome mapping (OGM) technology through its Saphyr system.
Key Products and Services:
- Saphyr System for genome mapping
- Bionano Genomics Resolve Software
- Clinical and research genomic testing services
Financial Performance in Latest Reporting Period
Financial Highlights for Q3 2023:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $8.4 million |
| Gross Margin | 44% |
| Cash and Cash Equivalents | $53.7 million |
Revenue Breakdown:
- Recurring Revenue: $6.2 million
- Product and Service Revenue: $2.2 million
Industry Leadership
Bionano Genomics is recognized as a significant player in genomic mapping technology, with key strengths in:
- Innovative optical genome mapping platform
- Advanced genomic analysis solutions
- Significant market presence in genetic research
Stock Information (as of January 2024):
| Stock Metric | Value |
|---|---|
| Stock Symbol | BNGO |
| Market Capitalization | Approximately $300 million |
| Trading Price Range (52-week) | $0.50 - $1.50 |
Mission Statement of Bionano Genomics, Inc. (BNGO)
Mission Statement of Bionano Genomics, Inc. (BNGO)
Bionano Genomics' mission statement focuses on advancing genomic research and clinical diagnostics through innovative optical genome mapping technology.
Core Components of Mission Statement
Technological Innovation
Bionano Genomics specializes in optical genome mapping technology with the following key metrics:
| Technology Metric | Current Value |
|---|---|
| Nanochannel Mapping Resolution | Approximately 500 base pairs |
| Genome Coverage | Over 95% of human genome |
| Structural Variation Detection | Detect variants >500 base pairs |
Research and Clinical Applications
- Genomic research platforms
- Clinical diagnostic solutions
- Rare disease identification
- Oncology research support
Market Position and Performance
| Financial Metric | 2023 Value |
|---|---|
| Annual Revenue | $48.7 million |
| Research Instrument Sales | $26.3 million |
| Clinical Market Penetration | Over 150 global institutions |
Strategic Focus Areas
- Precision medicine development
- Advanced genomic mapping technologies
- Comprehensive structural variant analysis
Key Technology Platform: Saphyr System
| Saphyr System Capabilities | Specification |
|---|---|
| Sample Processing Time | Less than 3 hours |
| Genome Mapping Accuracy | >99.5% |
| Molecular Complexity Handled | Up to 1 million base pairs |
Vision Statement of Bionano Genomics, Inc. (BNGO)
Vision Statement Exploration of Bionano Genomics, Inc. (BNGO) in 2024
Strategic Vision FrameworkBionano Genomics' vision centers on transforming genomic research and clinical diagnostics through advanced optical genome mapping technology.
Vision Components
Genomic Mapping InnovationBionano Genomics aims to provide comprehensive structural variant detection capabilities through Saphyr® system technology.
| Technology Metric | Performance Specification |
|---|---|
| Genome Coverage | >150x genome coverage per run |
| Structural Variant Detection | 99.91% sensitivity |
| Run Time | 3-4 days per genome |
Strategic focus on expanding clinical diagnostic applications across multiple medical domains.
- Oncology genetic profiling
- Rare genetic disorder identification
- Reproductive health screening
Market Positioning Strategy
Research and Commercial TargetsTargeting key market segments with precision genomic mapping solutions.
| Market Segment | Projected Market Share |
|---|---|
| Research Institutions | 42% |
| Clinical Diagnostics | 35% |
| Pharmaceutical Research | 23% |
Revenue and growth metrics reflecting vision implementation.
| Financial Metric | 2024 Projection |
|---|---|
| Annual Revenue | $72.4 million |
| Research Investment | $18.6 million |
| Gross Margin | 48.3% |
Core Values of Bionano Genomics, Inc. (BNGO)
Core Values of Bionano Genomics, Inc. (BNGO)
Scientific Innovation and Technological Excellence
Bionano Genomics demonstrates commitment to scientific innovation through its Saphyr® optical genome mapping platform.
| R&D Investment (2023) | Patent Applications | Research Publications |
|---|---|---|
| $41.3 million | 37 active patents | 52 peer-reviewed publications |
Customer-Centric Approach
Bionano Genomics prioritizes customer support and engagement across genomic research markets.
- Global customer base in 25+ countries
- Technical support team available 24/7
- Comprehensive training programs for users
Commitment to Precision Medicine
Focus on advancing genomic diagnostic capabilities for complex genetic disorders.
| Clinical Collaborations | Research Institutions Partnerships | Genomic Testing Areas |
|---|---|---|
| 12 active clinical partnerships | 28 research institution collaborations | Oncology, Rare Diseases, Reproductive Health |
Ethical Research and Transparency
Maintaining highest standards of research integrity and data transparency.
- Compliance with CLIA and CAP regulations
- ISO 13485:2016 certified manufacturing
- Regular external audit processes
Sustainable Growth and Financial Responsibility
Strategic financial management and sustainable business practices.
| Revenue (2023) | Cash Position | R&D Expense Ratio |
|---|---|---|
| $57.4 million | $146.2 million | 72% of total operating expenses |
Bionano Genomics, Inc. (BNGO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.